Agrenvec is a European biotech specialized in plant production of mammalian recombinant proteins and antibodies for the R&D market. Was created as a start-up company in 2002 with the in-licensing of several patents from the INIA (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria).
We are focused on the development, manufacture and marketing, of products and services for the R&D and Industrial markets. Our Company owns a patented technology platform allowing us a high-throughput production of Animal free fully active recombinant proteins with complex 3D structure and with a purity of 97%.